Investor information

EderaGen AS (est. 2018) is a privately owned Norwegian shareholders company with its registered office in Bergen. It is the mother company of a small group of companies. The sales subsidiary EderaGen Helse AS (est. 2020) is dedicated to food supplements for strengthening innate immunity and for gut health. The other subsidiary EderaGen Pharma AS (est. 2026) is dedicated to pharmaceutical development.

EderaGen builds its business on the groundbreaking invention Deconstructed Soil Composition for regulating the gut microbiota in humans and animals. It is strikingly different from all other products and does not belong to any existing category. Instead, it is the world’s first product in a class of its own, an ecoceuticum – a gut microbial ecosystem-modulating product. EderaGen owns six patents protecting the invention in their respective jurisdictions: Japan, United States, Canada, Europe (21 countries), Mexico, and Norway. Read more here.

Following a June 2025 emission of stock at a share premium, the share capital is NOK 2,906,505. As per October 2026, EderaGen has 43 shareholders, among whom professor emeritus Jan Raa owns a majority stake. Many shareholders are knowledgeable and merited within key business areas of the Company. All shares carry equal rights to vote and equal rights to dividends. Purchase and sale of shares are conditional on the approval of the Board of Directors. There are no pre-emption rights.

All international patents were issued after the June 2025 emission of stock, and the process of capitalizing on the business opportunities vested in the worldwide patent portfolio has commenced. Economic muscle of a certain calibre is required to pursue licensing related activities. Moreover, the dedicated subsidiary EderaGen Pharma has entered an early phase of exploring whether products based on the patent enhance the therapeutic effect of immunotherapy. The rationale is based on literature studies documenting that the efficacy of cancer antibodies can be significantly reduced—or fail to manifest—when certain gut bacteria become less prevalent and others become dominant. This is highly relevant to EderaGen, as it is a fact that the company’s ecoceuticum favors the therapeutic efficacy of cancer antibodies, while suppressing those species that have the opposite effect.

Strengthening EderaGen financially is seen as vital to cope with expansion, and the previously announced emission of stock at a share premium may take place within months. Inquiries from interested investors should be addressed to the CEO at kea@ederagen.no.